G. Bodoky

Continuum of care and survival in patients with metastatic colorectal cancer: results of the real-world prospective, longitudinal cohort PROMETCO study

Miriam Koopman, Rocio García‐Carbonero, C. Pinto, A. Mitroshkin et autres

Background: PROMETCO is the first international, prospective study investigating the continuum of care, including prescribing patterns, efficacy and safety in patients with metastatic colorectal cancer (mCRC) at later therapy lines in a real-world setting. Materials and methods: Adults with mCRC and two …

nl, es, it, de, hu, fr, gb (code pays fourni par la source)

Supplementary Table S3 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

Recurrence-free rates including 90% confidence intervals at different time points

Supplementary Figure S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

Overall survival. Kaplan-Meier curve of overall survival (including unstratified hazard ratio) – comparison between patients randomized to aspirin (in red) versus placebo (in blue).

Supplementary Figure S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

Sensitivity analyses accounting for non-proportional hazards. Sensitivity analyses accounting for non-proportional hazards using restricted mean survival time. The separating curves over time indicate the benefit of aspirin over placebo on disease-free survival.

Supplementary Table S1 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

Representativeness of study participants

Data from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

AbstractPurpose: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated colon cancer. Patients and Methods: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage …

Supplementary Table S2 from Adjuvant Aspirin Treatment in PIK3CA-Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

Impact on disease-free survival by number of tablets taken per day in Cox regression analysis

Adjuvant Aspirin Treatment in PIK3CA -Mutated Colon Cancer Patients: The SAKK 41/13 Prospective Randomized Placebo-Controlled Double-Blind Trial

Ulrich Güller, Stefanie Hayoz, Daniel Horber, Wolfram Jochum et autres

PURPOSE: We assessed the benefit of adjuvant aspirin in patients with resected phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated colon cancer. PATIENTS AND METHODS: This was a phase III, prospective, randomized, placebo-controlled, double-blind, multicenter, and multinational trial. Patients with resected colon cancer stage …

ch, de, be, hu, fr (code pays fourni par la source)

74P Real-world progression-free and overall survival of patients with metastatic colorectal cancer according to first and second-line treatment regimen: PROMETCO study

M. Koopman, R. Garcia-Carbonero, Carmine Pinto, A. Mitroshkin et autres

nl, es, it, de, hu, gb, ar, cz, gr, pt, at, be, hr, si, fr (code pays fourni par la source)

604P Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)

Miriam Koopman, R. Garcia-Carbonero, Carmine Pinto, A. Mitroshkin et autres

nl, es, de, hu, fr, it, ar, gb (code pays fourni par la source)

Real-world study to evaluate the clinical performance of a computational method in precision oncology.

Anna Dirner, G. Bodoky, Gábor Lakatos, Dóra Lakatos et autres

e13631 Background: In recent years, precision medicine has increasingly been integrated into routine clinical oncology care. However, interpretation of large amounts of biological information can be challenging in daily clinical practice settings. We previously demonstrated that digital drug assignment (DDA), an artificial …

hu, fr (code pays fourni par la source)

Table S1 from Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Josep Tabernero, Atsushi Ohtsu, Kei Muro, Eric Van Cutsem et autres

Table S1 describes REGARD exposure-safety outcomes for Grade >=3 hypertension.